Triplet therapy shows strongest survival benefit in mHSPC with visceral disease
/0 Comments/in Review/by MaxMetformin and Prostate Cancer: A Review of STAMPEDE Trial from The Lancet
/0 Comments/in Review/by MaxInnovations in Prostate Cancer Treatment: Antibody-Based Radioligand Therapy and Combinations Show Promise
/0 Comments/in Review/by MaxTransdermal Estradiol: A Cost-Saving, Quality-of-Life Boost for Prostate Cancer Therapy
/0 Comments/in Review/by MaxNavigating Treatment Options after Triplet Therapy Failure in Prostate Cancer: Should a Second ARPI Be Considered?
/0 Comments/in Review/by MaxMetastasis-Directed Therapy: A Paradigm Shift in Metastatic Prostate Cancer Treatment
/0 Comments/in Review/by MaxPARP Inhibitors in Prostate Cancer: Navigating the Complexities of DNA Repair
/0 Comments/in Review/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA MYC NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- Anti-PD-L1 Therapy Shows Promise for MMR-Deficient Metastatic Prostate Cancer August 30, 2025
- Phase 2 Trial: Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response via Modulation of Androgen Receptor (SPIDERMAN) August 29, 2025
- Phase 1: AMG 509 (Xaluritamig) for Metastatic Hormone Sensitive Prostate Cancer August 29, 2025
- Phase 1: Lartesertib and Tuvusertib Target DNA Repair to Fight Resistant Tumors August 29, 2025